Jump to contents

Researcher Information

last modified:2019/02/15

Professor KATO Yukio

Mail Laboratory Website

Faculty, Affiliation

Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences

College and School Educational Field


Division of Life Sciences, Graduate School of Natural Science and Technology
School of Pharmaceutical Sciences, College of Medical, Pharmaceutical and Health Sciences
School of Pharmacy, College of Medical, Pharmaceutical and Health Sciences

Laboratory

Department of Molecular Pharmacotherapeutics TEL:076-234-4465 FAX:076-234-4465

Academic Background

【Academic background(Doctoral/Master's Degree)】
The University of Tokyo Doctor Pharmaceutical Sciences 199307 Unfinished course
【Academic background(Bachelor's Degree)】
The University of Tokyo 199003
【Degree】
Ph.D.

Career

Kanazawa University Faculty of Pharmaceutical Sciences(2002/06/01-2008/08/31)
University of Tokyo Faculty of Pharmaceutical Sciences(1993/08/01-2002/05/31)
Kanazawa University Faculty of Pharmacy(2008/09/01-)
National Institutes of Health National Institute of Child Health & Visiting Fellow(2001/04/01-2002/05/31)

Year & Month of Birth

1967/09

Academic Society


Japanese Society for the Study of Xenobiotics



International Society for the Study of Xenobiotics
The Japanese Pharmacological Society

Award

○Banyu Young Scientist Award for Pharmaceutics(2000/04/01)
○New Investigator Award(2006/05/26)
○New Investigator Award(2006/11/29)
○New Investigator Award(2008/05/21)

Specialities

Pharmacokinetics、Pharmacotherapeutics、protein-protein interaction

Speciality Keywords

Pharmacokinetics, Pharmacotherapeutics, membrane permeation, transporter, protein-protein interaction

Research Themes

Transporter-mediated disposition and delivery of therapeutic agents

Regulation mechanisms of localization and function of xenobiotic transporters

Pharmacokinetics and delivery of biologically active proteins and macromolecules

Books

  •  Peptide and protein delivery targeted to receptor-mediated endocytosis. Crit 14 3 173-219 1997
  •  Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. 42 (suppl) S44-S49 1997
  •  Sugiura T, Kato Y, Tsuji A.  Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition.  116 2 238-246 2006/11
  •  Kato Y, Watanabe C, Tsuji A.  Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors.  27 5 487-500 2006/04
  •  Kato Y Xenobiotic transporter-adaptor network.  22 6 401-408 2007/12

show all

  •  Sugiura T, Shimizu T, Kijima A, Minakata S, Kato Y. PDZ adaptors: Their regulation of epithelial transporters and involvement in human diseases. 100 9 3620-3635 2011/07

Papers

  •  Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: Phenylarsine oxide-sensitive and -insensitive pathways. Kato Y, Sato H, Ichikawa M, Suzuki H, Sawada Y, Hanano M, Fuwa T, Sugiyama Y.  PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AME 89 18 8507-8511 1992/09
  •  Importance of the liver in plasma clearance of hepatocyte growth factors in rats.  Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 263 (5 Pt 1) G642-G649 1992
  •  Binding, internalization, degradation, and mitogenic effect of epidermal growth factor in cultured rat hepatocytes.  Kato Y, Sugiyama Y.  STP PHARMA SCIENCES 3 1 75-82 1993
  •  Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride-intoxicated rats.  Liu KX, Kato Y, Yamazaki M, Higuchi O, Nakamura T, Sugiyama Y.  HEPATOLOGY 17 4 651-660 1993
  •  Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolidine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space.  Ichikawa M, Kato Y, Miyauchi S, Sawada Y, Iga T, Fuwa T, Hanano M, Sugiyama Y.  JOURNAL OF HEPATOLOGY 20 2 190-200 1994

show all

  •  Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity.  Kato Y, Liu KX, Nakamura T, Sugiyama Y.  HEPATOLOGY 20 2 417-424 1994
  •  Change in hepatic handling of hepatocyte growth factor during liver regeneration in rats.  Liu KX, Kato Y, Terasaki T, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 269 (5 Pt 1) G745-G753 1995
  •  Contribution of parenchymal and non-parenchymal liver cells to the clearance of hepatocyte growth factor from the circulation in rats.  Liu KX, Kato Y, Terasaki T, Aoki S, Okumura K, Nakamura T, Sugiyama Y.  PHARMACEUTICAL RESEARCH 12 11 1737-1740 1995
  •  The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.  Shin HC, Kato Y, Shitara Y, Yamada T, Nakamura T, Hisaka A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 278 2 607-613 1996
  •  Cell density-dependent mitogenic effect and -independent cellular handling of epidermal growth factor in primary cultured rat hepatocytes.  Hamada T, Kato Y, Terasaki T, Sugiyama Y.  JOURNAL OF HEPATOLOGY 26 2 353-360 1997
  •  Kinetic analysis of transcytosis of epidermal growth factor in Madin-Darby Canine Kidney epithelial cells. Kozu A, Kato Y, Shitara Y, Hanano M, Sugiyama Y.  PHARMACEUTICAL RESEARCH 14 9 1228-1235 1997
  •  Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. Liu KX, Kato Y, Kato M, Kaku TI, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 273 5Pt1 E891-E897 1997
  •  Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics.  Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 25 9 1039-1044 1997
  •  Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 283 2 520-527 1997
  •  Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123.  Shin HC, Kato Y, Yamada T, Niinuma K, Hisaka A, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 272 (5 Pt 1) G979-G986 1997
  •  Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. Chu XY, Kato Y, Niinuma K, Sudo KI, Hakusui H, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 281 1 304-314 1997
  •  Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Chu XY, Kato Y, Sugiyama Y.  Cancer Res. 57 10 1934-1938 1997
  •  Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. Masuda M, I'izuka Y, Yamazaki M, Nishigaki R, Kato Y, Ni'inuma K, Suzuki H, Sugiyama Y.  CANCER RESEARCH 57 16 3506-3510 1997/10
  •  Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2- methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide.  Niinuma K, Takenaka O, Horie T, Kobayashi K, Kato Y, Suzuki H, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 282 2 866-872 1997
  •  Human placental extract stimulates liver regeneration in rats.  Liu KX, Kato Y, Kaku T, Sugiyama Y.  BIOLOGICAL & PHARMACEUTICAL BULLETIN 21 1 44-49 1998
  •  Importance of hepatic first-pass removal in metastasis of colon carcinoma cells: Kinetics of tumor cells. Mizuno N, Kato Y, Izumi Y, Irimura T, Sugiyama Y.  JOURNAL OF HEPATOLOGY 28 5 865-877 1998
  •  Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver. Mizuno N, Kato Y, Shirota K, Izumi Y, Irimura T, Harashima H, Kiwada H, Motoji N, Shigematsu A, Sugiyama Y.  JOURNAL OF HEPATOLOGY 28 5 878-885 1998
  •  Protamine enhances the proliferative activity of hepatocyte growth factor in rats. Liu KX, Kato Y, Kaku TI, Matsumoto K, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 274 1Pt1 G21-G28 1998
  •  Effect of brefeldin A and lysosomotropic reagents on intracellular trafficking of epidermal growth factor and transferrin in Madin-Darby canine kidney epithelial cells.  Shitara Y, Kato Y, Sugiyama Y.  JOURNAL OF CONTROLLED RELEASE 55 1 35-43 1998
  •  Pharmacokinetics of erythropoietin in genetically anemic mice.  Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 26 2 126-131 1998
  •  Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. Liu KX, Kato Y, Kino I, Nakamura T, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 275 5Pt1 E835-E842 1998
  •  Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein.  Yamada T, Kato Y, Kusuhara H, Lemaire M, Sugiyama Y.  BIOLOGICAL & PHARMACEUTICAL BULLETIN 21 8 874-878 1998
  •  Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the Rat. Sasabe H, Kato Y, Tsuji A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 284 2 661-668 1998
  •  Biliary excretion mechanism of CPT-11 and its metabolites in humans: Involvement of primary active transporters. Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. CANCER RESEARCH 58 22 5137-5143 1998
  •  Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats. Kato M, Kato Y, Nakamura T, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 290 1 373-379 1999
  •  Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. Kato M, Kato Y, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 276 5Pt1 E887-895 1999
  •  Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. Kato Y, Akhteruzzaman S, Hisaka A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 288 2 568-574 1999
  •  Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. Akhteruzzaman S, Kato Y, Hisaka A, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 288 2 575-581 1999
  •  Primary active transport of organic anions on bile canalicular membrane in humans. Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY 276 5Pt1 G1153-1164 1999
  •  Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. Sasabe H, Kato Y, Terasaki T, Tsuji A, Sugiyama Y.  BIOPHARMACEUTICS & DRUG DISPOSITION 20 3 151-158 1999
  •  Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats. Han YH, Kato Y, Kusuhara H, Suzuki H, Shimoda M, Kokue E, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 276 3Pt1 E580-E587 1999
  •  Renal handling of biphosphonate alendronate in rats. Kino I, Kato Y, Lin JH, Sugiyama Y.  BIOPHARMACEUTICS & DRUG DISPOSITION 20 4 193-198 1999
  •  Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 290 3 1107-1115 1999
  •  Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats. Han YH, Kato Y, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 291 1 204-212 1999
  •  Active efflux of CPT-11 and its metabolites in human KB-derived cell lines Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 288 2 735-741 1999
  •  Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. Chu XY, Kato Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 27 4 440-441 1999
  •  Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1,1-dimethylethylaminocarbonyl)-4-[(furo[2,3B]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2R-phenylmethylpentanamide and P-glycoprotein by valspodar... Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 28 10 1238-1243 2000
  •  Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance- associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats.  Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 292 1 433-439 2000
  •  Binding and transport of methotrexate and its derivative, MX-68, across the brush-border membrane in the rat kidney. Han YH, Kato Y, Sugiyama Y. BIOPHARMACEUTICS & DRUG DISPOSITION 20 361-367 1999
  •  Hydroxyprolylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. Liu KX, Kato Y, Kaku TI, Santa T, Imai K, Yagi A, Ishizu T, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 294 2 510-515 2000
  •  Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the non-peptide angiotensin II antagonist, Telmisaltan. Nishino A, Kato Y, Igarashi T, Sugiyama Y.  Drug Metab. Dispos. 28 10 1146-1148 2000
  •  Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. Shirota K, Kato Y, Irimura T, Kondo H, Sugiyama Y. BIOLOGICAL & PHARMACEUTICAL BULLETIN 24 3 316-319 2001
  •  Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. Nishiyama N, Kato Y, Sugiyama Y, Kataoka K.  PHARMACEUTICAL RESEARCH 18 7 1035-1041 2001
  •  Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K.  JOURNAL OF CONTROLLED RELEASE 77 1-2 27-38 2001
  •  Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. Mizuno N, Kato Y, Iwamoto M, Urae A, Amamoto T, Niwa T, Sugiyama Y.  PHARMACEUTICAL RESEARCH 18 8 1203-1209 2001
  •  Characterization of Novel Kidney-Specific Delivery System Using an Alkylglucoside Vector. Shirota K, Kato Y, Suzuki K, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 299 2 459-467 2001
  •  Investigation of 5-FU Disposition After Oral Administration of Capecitabine, a Triple-prodrug of 5-FU, Using a Physiologically Based Pharmacokinetic Model in a Human Cancer Xenograft Model: Comparison of the Simulated 5-FU ... Tsukamoto Y, Kato Y, Ura M, Horii I, Ishikawa T, Ishitsuka H, Sugiyama Y.  Biopharm. Drug Dispos. 22 1 1-14 2001
  •  A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y.  PHARMACEUTICAL RESEARCH 18 8 1190-1202 2001
  •  Physicochemical parameters responsible for the affinity of methotrexate analogs to rat canalicular multispecific organic anion transporter (cMOAT/MRP2). Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y.  PHARMACEUTICAL RESEARCH 18 5 579-586 2001
  •  Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-diamminopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4-benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats. Han YH, Kato Y, Watanabe Y, Terao K, Asoh Y, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 29 4Pt1 394-400 2001
  •  Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. Ueda K, Kato Y, Komatsu K, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 297 3 1036-1043 2001
  •  Structural basis for acidic cluster-dileucine sorting signal recognition by VHS domains. Misra S, Puertollano R, Kato Y, Bonifacino JS, Hurley JH. NATURE 415 6874 933-937 2002
  •  Phosphoregulation of sorting signal-VHS domain interactions by a direct electrostatic mechanism. Kato Y, Misra S, Puertollano R, Hurley JH, Bonifacino JS. NATURE STRUCTURAL BIOLOGY 9 7 532-536 2002
  •  A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis.  Sato H, Kato Y, Hayasi E, Tabata T, Suzuki M, Takahara Y, Sugiyama Y.  PHARMACEUTICAL RESEARCH 19 11 1736-1744 2002
  •  pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes.  Maeda K, Kato Y, Sugiyama Y.  JOURNAL OF CONTROLLED RELEASE 82 1 71-82 2002
  •  Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.  Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y.  PHARMACEUTICAL RESEARCH 19 2 147-153 2002
  •  The Potential for an Interaction between MRP2 (ABCC2) and Various Therapeutic Agents: Probenecid as a Candidate Inhibitor of the Biliary Excretion of Irinotecan Metabolites.  Horikawa M, Kato Y, Tyson CA, Sugiyama Y.  DRUG METABOLISM AND PHARMACOKINETICS 17 1 23-33 2002
  •  Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats.  Horikawa M, Kato Y, Sugiyama Y.  PHARMACEUTICAL RESEARCH 19 9 1345-1353 2002
  •  Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. Gotoh Y, Kato Y, Stieger B, Meier PJ, Sugiyama Y.  AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 282 6 E1245-E1254 2002
  •  Gender difference in the urinary excretion of organic anions in rats. Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 302 2 483-9 2002
  •  Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin.  Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 302 2 510-515 2002
  •  Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats.  Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 30 12 1393-1399 2002
  •  Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice.  Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K.  CANCER RESEARCH 63 24 8977-8983 2003
  •  Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes. Janvier K, Kato Y, Boehm M, Rose JR, Martina JA, Kim BY, Venkatesan S, Bonifacino JS. JOURNAL OF CELL BIOLOGY 163 6 1281-1290 2003
  •  Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans.  Horikawa M, Kato Y, Tyson CA, Sugiyama Y.  DRUG METABOLISM AND PHARMACOKINETICS 18 1 16-22 2003
  •  Function of uptake transporters for taurocholate and estradiol 17beta-d-glucuronide in cryopreserved human hepatocytes.  Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y.  DRUG METABOLISM AND PHARMACOKINETICS 18 1 33-41 2003
  •  Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin.  Wang DS, Kusuhara H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y.  MOLECULAR PHARMACOLOGY 63 4 844-848 2003
  •  Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines.  Li Q, Sai Y, Kato Y, Tamai I, Tsuji A.  PHARMACEUTICAL RESEARCH 20 8 1119-1124 2003
  •  Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin.  Yagi Y, Shibutani S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y, Tsuji A.  DRUG METABOLISM AND PHARMACOKINETICS 18 6 381-389 2003
  •  Transporter-mediated renal handling of nafamostat mesilate.  Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A.  JOURNAL OF PHARMACEUTICAL SCIENCES 93 2 262-272 2004
  •  Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition.  Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A.  DRUG METABOLISM AND PHARMACOKINETICS 19 3 180-189 2004
  •  Characterization of renal excretion mechanism for a novel diuretic, M17055, in rats.  Nishimura T, Kato Y, Sai Y, Ogihara T, Tsuji A.  JOURNAL OF PHARMACEUTICAL SCIENCES 93 10 2558-2566 2004
  •  Differential involvement of multidrug resistance-associated protein 1 and P-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y.  JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 310 2 648 2004
  •  Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population.  Kawasaki Y, Kato Y, Sai Y, Tsuji A.  JOURNAL OF PHARMACEUTICAL SCIENCES 93 12 2920-2926 2004
  •  Screening of the interaction between xenobiotic transporters and PDZ proteins Kato Y, Yoshida K, Watanabe C, Sai Y, Tsuji A.  PHARMACEUTICAL RESEARCH 21 10  1886-1894 2004
  •  Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells. Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. DRUG METABOLISM AND PHARMACOKINETICS 20 6 491-495 2005
  •  Multidrug resistance-associated protein 1 functions as an efflux pump of xenobiotics in the skin.  Li Q, Kato Y, Sai Y, Imai T, Tsuji A. PHARMACEUTICAL RESEARCH 22 6 842-846 2005
  •  PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. Kato Y, Sai Y, Yoshida K, Watanabe C, Hirata T, Tsuji A. MOLECULAR PHARMACOLOGY 67 3  734-743 2005
  •  Na+/ H+ exchanger 3 affects transport property of H+/oligopeptide transporter 1. Watanabe C, Kato Y, Ito S, Kubo Y, Sai Y and Akira Tsuji. DRUG METABOLISM AND PHARMACOKINETICS 20 6 443-451 2005
  •  A time- and cost-saving method of producing rat polyclonal antibodies. Wakayama T, Kato Y, Utsumi R, Tsuji A, Iseki S. ACTA HISTOCHEMICA ET CYTOCHEMICA 39 3 79-87 2006
  •  Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K. BIOCHEMICAL PHARMACOLOGY 72 8 1042-1050 2006
  •  Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, Miyamoto K. INTERNATIONAL JOURNAL OF PHARMACEUTICS 309 1-2 81-86 2006
  •  Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. DRUG METABOLISM AND DISPOSITION 34 8 1423-1431 2006
  •  Carrier-mediated hepatic uptake of a novel non-renal excretion type uric acid generation inhibitor, Y-700. Sai Y, Kato Y, Nakamura K, Kato S, Nishimura T, Kubo Y, Tamai I, Yang S, Hu Z, Yamada I and Tsuji A. JOURNAL OF PHARMACEUTICAL SCIENCES 95 2 336-347 2006
  •  Characterization of the transdermal transport of flurbiprofen and indomethacin. Li Q, Tsuji H, Kato Y, Sai Y, Kubo Y, Tsuji A. JOURNAL OF CONTROLLED RELEASE 110 3 542-556 2006
  •  Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2. Sugiura T, Kato Y, Kubo Y and Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 21 5 375-383 2006
  •  PDZ adaptor protein PDZK2 stimulates transport activity of organic cation/carnitine transporter OCTN2 by modulating cell-surface expression. Watanabe C, Kato Y, Sugiura T, Kubo Y, Wakayama T, Iseki S and Tsuji A. DRUG METABOLISM AND DISPOSITION 34 11 1927-1934 2006
  •  Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. Kato Y, Sugiura M, Sugiura T, Wakayama T, Kubo Y, Kobayashi D, Sai Y, Tamai I, Iseki S, Tsuji A. MOLECULAR PHARMACOLOGY 70 3 829-837 2006
  •  Heterophilic binding of the adhesion molecules poliovirus receptor and immunoglobulin superfamily 4A in the interaction between mouse spermatogenic and Sertoli cells. Wakayama T, Sai Y, Ito A, Kato Y, Kurobo M, Murakami Y, Nakashima E, Tsuji A, Kitamura Y, Iseki S. BIOLOGY OF REPRODUCTION 76 6 1081-1090 2007
  •  Characterization of the hepatic disposition of lanoteplase, a rationally designed variant of tissue plasminogen activator in rodents. Komoriya K, Kato Y, Hayashi Y, Ohsuye K, Nishigaki R, Sugiyama Y.  DRUG METABOLISM AND DISPOSITION 35 3 469-475 2007
  •  Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: Involvement of organic anion transporting polypeptide (OATP)-B. Nishimura T, Kubo Y, Kato Y, Sai Y, Ogihara T and Tsuji A.  PHARMACEUTICAL RESEARCH 24 1 90-98 2007
  •  Functional expression of stereoselective metabolism of cephalexin by exogenous transfection of oligopeptide transporter PEPT1. Mitsuoka K, Kato Y, Kubo Y, Tsuji A.  DRUG METABOLISM AND DISPOSITION 35 3 356-362 2007
  •  Transporter-mediated Hepatic Uptake of Ulifloxacin, an Active Metabolite of a Prodrug-type New Quinolone Antibiotic Prulifloxacin in Rats. Yagi Y, Aoki M, Iguchi M, Shibasaki S, Kurosawa T, Kato Y, Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 22 5 350-357 2007
  •  Involvement of organic anion transport system in transdermal absorption of flurbiprofen. Ito K, Kato Y, Tsuji H, Nguyen HT, Kubo Y, Tsuji A. JOURNAL OF CONTROLLED RELEASE 124 1-2 60-68 2007
  •  Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. Nishimura T, Amano N, Kubo Y, Ono M, Kato Y, Fujita H, Kimura Y, Tsuji A.  DRUG METABOLISM AND DISPOSITION 35 8 1275-1284 2007
  •  The Rab8 GTPase regulates apical protein localization in intestinal cells. Sato T, Mushiake S, Kato Y, Sato K, Sato M, Takeda N, Ozono K, Miki K, Kubo Y, Tsuji A, Harada R, Harada A.  NATURE 448 7151 366-369 2007
  •  Cancer detection using a PET tracer, 11C-glycylsarcosine, targeted to H+/peptide transporter. Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y, Hiraiwa M, Noda A, Nakamura Y, Nishimura S, Tsuji A.  JOURNAL OF NUCLEAR MEDICINE 49 4 615-622 2008
  •  Cationic Polyrotaxanes effectively inhibit Uptake via Carnitine/Organic Cationic Transporter without cytotoxicity. Utsunomiya H, Katoono R, Yui N, Sugiura T, Kubo Y, Kato Y, Tsuji A. MACROMOLECULAR BIOSCIENCE 8 7 665-669 2008
  •  PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice. Sugiura T, Kato Y, Wakayama T, Silver DL, Kubo Y, Iseki S, Tsuji A. DRUG METABOLISM AND DISPOSITION 36 6 1181-1188 2008
  •  Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 23 3 207-215 2008
  •  Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. DRUG METABOLISM AND DISPOSITION 36 6 1088-1096 2008
  •  Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. Nishimura T, Kato Y, Amano N, Ono M, Kubo Y, Kimura Y, Fujita H, Tsuji A. PHARMACEUTICAL RESEARCH 25 11 2467-2476 2008
  •  L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules. Nakamura K, Ito K, Kato Y, Sugaya T, Kubo Y, Tsuji A. DRUG METABOLISM AND PHARMACOKINETICS 23 4 271-278 2008
  •  P-Glycoprotein (Abcb1) is involved in absorptive drug transport in skin. Ito K, Nguyen H-T, Kato Y, Wakayama T, Kubo Y, Iseki S, Tuji A. JOURNAL OF CONTROLLED RELEASE 131 3 198-204 2008
  •  Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. JOURNAL OF PHARMACEUTICAL SCIENCES 98 7 2529-2539 2009
  •  Investigation of the role of oligopeptide transporter PEPT1 and sodium/glucose cotransporter SGLT1 in intestinal absorption of their substrates using small GTP-binding protein Rab8 null mice. Kato Y, Sugiura T, Nakadera Y, Sugiura M, Kubo Y, Sato T, Harada A, Tsuji A. DRUG METABOLISM AND DISPOSITION 37 3 602-607 2009
  •  Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes. Liu KX, Kato Y, Matsumoto K, Nakamura T, Kaku T, Sugiyama Y. PHARMACEUTICAL RESEARCH 26 4 1012-1021 2009
  •  Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. Kano T, Kato Y, Ito K, Ogihara T, Kubo Y, Tsuji A. DRUG METABOLISM AND DISPOSITION 37 5  1009-16 2009
  •  Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. Kato S, Ito K, Kato Y, Wakayama T, Kubo Y, Iseki S, Tsuji A. PHARMACEUTICAL RESEARCH 26 6  1467-1476 2009
  •  Direct evidence for efficient transport and minimal metabolism of l-Cephalexin by PEPT1 in budded baculovirus fraction.  Mitsuoka K, Tamai I, Morohashi Y, Kubo Y, Saitoh R, Tsuji A, Kato Y.  BIOLOGICAL & PHARMACEUTICAL BULLETIN 32 8  1459-1461 2009
  •  Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. Kato S, Kato Y, Nakamura T, Sugiura T, Kubo Y, Deguchi Y, Tsuji A.  BIOPHARMACEUTICS & DRUG DISPOSITION 30 9 495-507 2009
  •  Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1.  Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, Kagaya T, Wakayama T, Hirayama A, Sugimoto M, Sugihara K, Kaneko S, Soga T, Asano M, Tomita M, Matsui T, Wada M, Tsuji A.  PHARMACOLOGICAL RESEARCH 27 5 832-840 2010
  •  Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells.  Mitsuoka K, Kato Y, Miyoshi S, Murakami Y, Hiraiwa M, Kubo Y, Nishimura S, Tsuji A.  EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES 40 3 202-208 2010
  •  OCTN2 is associated with carnitine transport capacity of rat skeletal muscles.  Furuichi Y, Sugiura T, Kato Y, Shimada Y, Masuda K.  200 1 57-64 2010
  •  Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver.  Sugiura T, Kato S, Shimizu T, Wakayama T, Nakamichi N, Kubo Y, Iwata D, Suzuki K, Soga T, Asano M, Iseki S, Tamai I, Tsuji A, Kato Y.  DRUG METABOLISM AND DISPOSITION 38 10 1665-1672 2010
  •  Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters.  Meng Q, Liu Q, Wang C, Sun H, Kaku T, Kato Y, Liu K.  25 4 320-327 2010
  •  PDZK1 regulates organic anion transporting polypeptide Oatp1a in mouse small intestine.  Sugiura T, Otake T, Shimizu T, Wakayama T, Silver DL, Utsumi R, Nishimura T, Iseki S, Nakamichi N, Kubo Y, Tsuji A, Kato Y.  DRUG METABOLISM AND PHARMACOKINETICS 25 6 588-598 2010
  •  Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-Increasing agent.  Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, Kato Y.  DRUG METABOLISM AND DISPOSITION 39 6 1088-1096 2011
  •  Effect of knockdown of ezrin, radixin and moesin on P-glycoprotein function in HepG2 cells. Kano T, Wada S, Morimoto K, Kato Y, Ogihara T. JOURNAL OF PHARMACEUTICAL SCIENCES 100 12 5308-5314 2011
  •  PDZK1 Regulates Breast Cancer Resistance Protein in Small Intestine.  Shimizu T, Sugiura T, Wakayama T, Kijima A, Nakamichi N, Iseki S, Silver DL, Kato Y.  DRUG METABOLISM AND DISPOSITION 印刷中 印刷中 印刷中 2011
  •  Muscle contraction increases carnitine uptake via translocation of OCTN2. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 418 4 774-779 2012
  •  Functional expression of carnitine/organic cation transporter OCTN1 in mouse brain neurons: Possible involvement in neuronal differentiation.  NEUROCHEMISTRY INTERNATIONAL 61 7 1121-1132 2012
  •  Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans.  JOURNAL OF PHARMACEUTICAL SCIENCES 102 1 237-249 2013
  •  ATP binding cassette transporters in two distinct compartments of skin contribute to transdermal absorption of a typical substrate. JOURNAL OF CONTROLLED RELEASE 165 1 54-61 2013
  •  Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. TOXICOLOGICAL SCIENCES 132 1 32-42 2013
  •  Displays of mouse pup retrieval as paternal parental behaviour following communicative interaction with maternal mates. Liu H-X, Lopatina O, Higashida C, Fujimoto H, Akther S, Inzhutova A, Liang M, Zhong J, Tsuji T, Yoshihara T, Sumi K, Ishiyama M, Ma W-J, Ozaki M, Yagitani S, Yokoyama S, Mukaida N, Sakurai T, Hori O, Yoshioka K, Hirao A, Kato Y, Ishihara K, Kato I, Okamoto H, Cherepanov SM, Salmina A, Hirai H, Asano M, Brown DA, Nagano I, Higashida H.  Nat Commun 4 1346 2013
  •  Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine in vivo. Yano K, Tomono T, Sakai R, Kano T, Morimoto K, Kato Y, Ogihara T.  J Pharm Sci 102 8 2875-2881 2013
  •  Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. Nakamichi N, Shima H, Asano S, Ishimoto T, Sugiura T, Matsubara K, Kusuhara H, Sugiyama Y, Sai Y, Miyamoto KI, Tsuji A, Kato Y.  J Pharm Sci 102(9): , 2013. 102 9 3407-3417 2013
  •  Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans.  Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y and Kato Y.  Pharm Res 31 31 1 204-215 2014
  •  Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in human.  Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, Horikawa M, Nakamichi N, Ishiwata N and Kato Y. Drug Metab Dispos 42 4 726-734 2014
  •  Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons.  IshimotoT, Nakamichi N, Hosotani H, Masuo Y, Sugiura T and Kato Y.  PLoS One 9 2 e89434 2014
  •  Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury.  Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K and Matsumoto K.  Pharmacology 94 3-4 190-187 2014
  •  Distinct Alterations in ABC Transporter Expression in Liver, Kidney, Small Intestine, and Brain in Adjuvant-induced Arthritic Rats. Kawase A, Norikane S, Okada A, Adachi M, Kato Y, Iwaki M.  J Pharm Sci 103 8 2556-2564 2014
  •  Decreased radixin function for ABC transporters in liver in adjuvant-induced arthritis rats.  Kawase A, Sakata M, Yada N, Nakasaka M, Shimizu T, Kato Y, Iwaki M.  J Pharm Sci 103 12 4058-4065 2014
  •  Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes.  Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N.  Ann Rheum Dis 75 4 652-659 2016
  •  Organic Cation Transporter Octn1-mediated Uptake of Food-derived Antioxidant Ergothioneine into Infiltrating Macrophages during Intestinal Inflammation in Mice.  Shimizu T, Masuo Y, Takahashi S, Nakamichi N and Kato Y.  Drug Metab Pharmacokinet 30 3 231-239 2015
  •  Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice.  Shimizu T, Kijima A, Masuo Y, Ishimoto T, Sugiura T, Takahashi S, Nakamichi N, Kato Y.  Chem Pharm Bull 38 5 774-780 2015
  •  Dipeptide species regulate nutrient signalling essential for the maintenance of chronic myelogenous leukaemia stem cells. Naka K, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae E, Mohney R, Stirdivant SM, Oshima H, Oshima M, Kim DW, Nakauchi H, Takihara Y, Kato Y, Ooshima A, Kim SJ.  Nat Commun 6 8039 2015
  •  Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure.  Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y.  Pharm Res 33 2 269-282 2016
  •  Myoglobin and the Regulation of Mitochondrial Respiratory Chain Complex IV.  Yamada T, Takakura H, Jue T, Hashimoto T, Ishizawa R, Furuichi Y, Kato Y, Iwanaka N, Masuda K.  J Physiol  594 2 483-495 2016
  •  Localizatoin of xenobiotic transporter OCTN1/SLC22A4 in hepatic stellate cells and its protective role in liver fibrosis. Tang Y, Masuo Y, Sakai Y, Wakayama T, Sugiura T, Harada R, Futatsugi A, Komura T, Nakamichi N, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kaneko S, Kato Y.  J Pharm Sci 105 5 1779-1789 2016
  •  Transport of 3-fluoro-L--methyl-tyrosine (FAMT) by organic ion transporters explains renal background in [18F]FAMT positron emission tomography.  Wei L, Tominaga H, Ohgaki R, Wiriyasermkul P, Hagiwara K, Okuda S, Kaira K, Kato Y, Oriuchi N, Nagamori S, Kanai Y.  J Pharmacol Sci 130 2 101-109 2016
  •  A mutation in SLC22A4 encoding an organic cation transporter expressed in the cochlea strial endothelium causes human recessive non-syndromic hearing loss DFNB60. Ben Said M, Grati M, Ishimoto T, Zou B, Chakchouk I, Ma Q, Yao Q, Hammami B, Yan D, Mittal R, Nakamichi N, Ghorbel A, Neng L, Tekin M, Shi XR, Kato Y, Masmoudi S, Lu Z, Hmani M, Liu X.  Human Genetics 135 5 513-524 2016
  •  Food-derived hydrophilic antioxidant ergothioneine is distributed to the brain and exerts antidepressant effect in mice. Nakamichi N, Nakayama K, Ishimoto T, Masuo Y, Wakayama T, Sekiguchi H, Sutoh K, Usumi K, Iseki S, Kato Y.  Brain and Behavior 6 6 e00477 2016
  •  Characterization of long-lasting Oatp inhibition by typical inhibitor cyclosporine A and in vitro-in vivo discrepancy in its drug interaction potential in rats.  Taguchi T, Masuo Y, Kogi T, Nakamichi N, Kato Y.  J Pharm Sci 105(7): , 2016. 105 7 2231-2239 2016
  •  L503F variant of carnitine/organic cation transporter 1 efficiently transports metformin and other biguanides.  Futatsugi A, Masuo Y, Kawabata S, Nakamichi N, Kato Y.  J Pharm Pharmacol 68 9 1160-1169 2016
  •  Screening to identify multidrug resistance-associated protein inhibitors with neuroblastoma-selective cytotoxicity. Nakamichi N, Ishimoto T, Yamauchi Y, Masuo Y, Kato Y.  Biol Pharm Bull 39 10 1638-1645 2016
  •  P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids.  Hashimoto N, Nakamichi N, Yamazaki E, Oikawa M, Masuo Y, Schinkel AH, Kato Y.  Int J Pharm  521 (1-2) :365-373 2017
  •  Impairment of the carnitine/organic cation transporter 1-ergothioneine axis is mediated by intestinal transporter dysfunction in chronic kidney disease.  Shinozaki Y, Furuichi K, Toyama T, Kitajima S, Hara A, Iwata Y, Sakai N, Shimizu M, Kaneko S, Isozumi N, Nagamori S, Kanai Y, Sugiura T, Kato Y, Wada T.  Kid Int  92 6 1356-1369 2017
  •  Usefulness of kidney slices for functional analysis of apical reabsorptive transporters. Arakawa H, Washio I, Matsuoka N, Kubo H, Staub AY, Nakamichi N, Ishiguro N, Kato Y, Nakanishi T, Tamai I.  Sci Rep  7 1 12814 2017
  •  Carnitine/organic cation transporter OCTN1 negatively regulates activation in murine cultured microglial cells.  Ishimoto T, Nakamichi N, Nishijima H, Masuo Y, Kato Y.  Neurochem Res  43 1 107-119 2018
  •  Organic cation transporter 1 is responsible for hepatocellular uptake of the tyrosine kinase inhibitor pazopanib.  Ellawatty WEA, Masuo Y, Fujita K, Yamazaki E, Ishida H, Arakawa H, Nakamichi N, Abdelwahed R, Sasaki Y, Kato Y.  46 1 33-40 2018
  •  Evaluation of alteration in hepatic and intestinal BCRP function in vivo due to ABCG2 c.421C>A polymorphism based on PBPK analysis of rosuvastatin.  Futatsugi A, Toshimoto K, Yoshikado T, Sugiyama Y, Kato Y.  Drug Metab Dispos  46 5 749-757 2018

Conference Presentations

  • Organic cation transporter OCTN1 as possible target for lung pathology.(conference:Workshop on Drug Transporters in the Lungs)(2016/09/22)
  • Role of ABC xenobiotic transporters in drug disposition in the skin.(conference:The Best of the Rest – Drug Transport across Non-traditional Biological Barriers)(2015/10/25)
  • ABC transporters involved in xenobiotics disposition in the skin. (conference:Meet the Experts: Transporter Conference Tokyo 2015)(2015/05/13)
  • Possible roles of xenobiotics transporter OCTN1/SLC22A4 in inflammatory diseases of digestive organs(2014/11/01)

Arts and Fieldwork

Patent

Theme to the desired joint research

○Transporter-mediated drug uptake and efflux
○Drug metabolism and disposition using gene-knockout animals
○Physiologically-based pharmacokinetic analysis of transporter-mediated drug interaction

Grant-in-Aid for Scientific Research

○「肝障害時における肝細胞増殖因子の体内動態機構の解析」(1994-1994) 
○「肝細胞増殖因子の受容体非介在性消失機構の解析」(1995-1995) 
○「生理活性ペプチド受容体を標的としたドラッグデリバリーシステムの細胞内挙動の制御」(1996-1996) 
○「サイトカインの非線形体内動態機構に基づいた新規デリバリーシステムの開発」(1997-1998) 
○「肝細胞膜に発現するトランスポーターの分子機能におけるシンクロナイゼーション」(1999-2000) 
○「多彩な生物活性を有する肝細胞増殖因子のホメオスタシスに基づいた臓器特異的送達」(1999-2000) 
○「異物排出トランスポーター群の上皮細胞アピカル膜局在を制御する分子シグナル」(2004-2004) 
○「薬物取り込み・排出トランスポーターの細胞膜ソーティングの分子機構と薬理学的意義」(2004-2005) 
○「抗癌剤の消化管毒性回避を目指した小腸上皮細胞取り込み機構の分子論的解析」(2004-2004) 
○「肝腎トランスポーターを介した薬物間相互作用の分子基盤」(2004-2005) 
○「薬物動態制御因子としてのトランスポーターアダプターの役割」(2006-2007) 
○「医薬品の薬効・毒性標的としてのトランスポーター・アダプターネットワーク」(2008-2010) 
○「トランスポートフォトコンバーター:多様な薬の生体膜透過を光に変換する新規計測技術」(2009-2010) 
○「ペプチドトランスポーターを利用した腫瘍細胞トリプルブロック分子標的薬の開発」(2011-2012) 
○「抗酸化物質膜輸送体を標的とした臓器慢性疾患防御の研究と治療への応用」(2012-2015) 
○「ABC膜輸送体を標的とする経皮薬物デリバリーシステムの開発研究」(2013-2014) 

Classes (Bachelors)

○Seminar in Clinical Pharmacy 2(2017)
○Basic Anatomy(2017)
○Experiments in Pharmaceutical Practice 3(2017)
○Introduction to Region-studies(2017)
○Drug Therapeutics 2(2017)
○Drug Therapeutics 1(2017)
○Seminar in Pharmaceutical Practice(2017)
○Basic Drug Development(2017)
○Medicinal Chemistry(2017)
○Seminar in Drug Therapeutics(2017)
○World of Coffee(2016)
○Overseas Active Learning in Pharmaceutical Sciences 2(2016)
○World of Coffee(2016)
○Drug Therapeutics 1(2016)
○Drug Therapeutics 2(2016)
○Basic Anatomy(2016)
○Seminar in Drug Therapeutics(2016)
○Experiments in Pharmaceutical Practice 3(2016)
○Basic Drug Development(2016)
○Seminar in Clinical Pharmacy 2(2016)
○Laboratory Rotation 2(2016)
○Medicinal Chemistry(2016)
○Overseas Active Learning in Pharmaceutical Sciences 1(2016)
○Introduction to Region-studies(2016)
○Freshman Seminar I(2016)
○Lecture on Life in Campus and Society(2016)

Classes (Graduate Schools)

○Prediction and Evaluation of Ddrug Efficacy(2017)
○Drug Metabolism(2017)
○Advanced Seminar on Precision Medicine(2017)
○Advanced Course of ADME Studies for Drug Development(2017)
○Pharmaceutical Therapeutics(2017)
○Molecular Pharmaceutics(2017)
○Introduction to Presicion Medicine(2017)
○Pharmaceutical Therapeutics(2016)

International Project

International Students

Lecture themes

Others (Social Activities)

To Page Top